The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.

For authors of Research Articles that have been declined for publication at an AACR journal, the AACR offers the corresponding author the option to easily transfer manuscript files and supporting ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

1Dana–Farber Cancer Institute, Boston, Massachusetts.

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Maryam Sarraf Yazdy, U.S. Food and Drug Administration, WO22 Room 2169, ...

1Department of Experimental Zoology, MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, P.R. China. 2Department of ...